There is research on this stock available only to PRO subscribers.
May. 7, 2013, 4:46 PM
Feb. 27, 2013, 1:35 PMShares of Bio-Rad (BIO +5%) move higher today after a solid Q4 earnings beat. Total sales rose 4.3% Y/Y, which was offset somewhat by a decline in gross margin to 55.9% from 56.5%. Sidoti upgrades the stock to Buy on the back of the upbeat report, while Jefferies ups its price target to $140 from $124 on higher cash flow forecasts. | Comment!
May. 1, 2012, 5:03 PM
Apr. 3, 2012, 12:22 PM
Jul. 5, 2011, 10:16 AMTPG's acquisition of Immucor (BLUD +30%) fails to spur comparables Bio-Rad Laboratories (BIO -0.7%) and Gen-Probe (GPRO -1.1%). Takeout multiples were below current diagnostics multiples, Leerink notes, and the P-E buyout likely means there was little interest in BLUD from strategic acquirers. | 1 Comment
BIO vs. ETF Alternatives
Bio-Rad Laboratories Inc manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials.
Other News & PR